Mucosal B Cells Are Associated with Delayed SIV Acquisition in Vaccinated Female but Not Male Rhesus Macaques Following SIVmac251 Rectal Challenge

PLoS Pathogens

Volumn 11, Issue 8, 2015, Pages

  Tuero, Iskra ^a   Mohanram, Venkatramanan ^a   Musich, Thomas ^a   Miller, Leia ^a   Vargas Inchaustegui, Diego A ^a   Demberg, Thorsten ^a   Venzon, David ^a   Kalisz, Irene ^b   Kalyanaraman, V S ^b   Pal, Ranajit ^b   Ferrari, Maria Grazia ^b   LaBranche, Celia ^c   Montefiori, David C ^c   Rao, Mangala ^d   Vaccari, Monica ^a   Franchini, Genoveffa ^a   Barnett, Susan W ^e   Robert Guroff, Marjorie ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^e Novartis Vaccine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ERDOSTEINE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 140; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MIFAMURTIDE; NEUTRALIZING ANTIBODY; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ANTIBODY;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SECRETING CELL; ANTIGEN BINDING; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOSYLATION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MALE; MEMORY CELL; MUCOSA CELL; NONHUMAN; PLASMA CELL; RECTUM DISEASE; SEX DIFFERENCE; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VIREMIA; ANIMAL; B LYMPHOCYTE; BLOOD; CELLULAR IMMUNITY; IMMUNOLOGY; INTESTINE MUCOSA; MUCOSAL IMMUNITY; RECTUM; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME;

ANIMALS; ANTIBODIES, VIRAL; B-LYMPHOCYTES; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; INTESTINAL MUCOSA; MACACA MULATTA; MALE; RECTUM; SAIDS VACCINES; SEX FACTORS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84940771353     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005101     Document Type: Article

References (80)

1. Klein SL, Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases. Bioessays. 2012; 34: 1050–1059. doi: 10.1002/bies.201200099 23012250
2. Addo MM, Altfeld M, Sex-based differences in HIV type 1 pathogenesis. J Infec Dis. 2014; 209 (Suppl 3): S86–S92.
3. Farzadegan H, Hoover DR, Astemborski J, Lyles CM, Margolick JB, Markham RB, et al. Sex differences in HIV-1 viral load and progression to AIDS. The Lancet. 1998; 352: 1510–1514.
4. Patterson LJ, Kuate S, Daltabuit-Test M, Li Q, Xiao P, McKinnon K, et al. Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route. Clin Vac Immunol. 2012; 19: 629–637.
5. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009; 361: 2209–2220. doi: 10.1056/NEJMoa0908492 19843557
6. Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS, et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infec Dis. 2012; 206: 431–441.
7. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012; 366: 1275–1286. doi: 10.1056/NEJMoa1113425 22475592
8. Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, Hwang KK, et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol. 2012; 86: 11521–11532. doi: 10.1128/JVI.01023-12 22896626
9. Mouquet H, Antibody B cell responses in HIV-1 infection. Trends Immunol. 2014; 35: 549–561. doi: 10.1016/j.it.2014.08.007 25240985
10. Lynch RM, Yamamoto T, McDermott AB, HIV vaccine research and discovery in the nonhuman primates model: a unified theory in acquisition prevention and control of SIV infection. Curr Opin HIV AIDS. 2013; 8: 288–94. 23666390
11. Rathore U, Kesavardhana S, Mallajosyula VV, Varadarajan R, Immunogen design for HIV-1 and influenza. Biochim Biophys Acta. 2014; 1844: 1891–1906. doi: 10.1016/j.bbapap.2014.05.010 24892211
12. Pancera M, Zhou T, Druz A, Georgiev IS, Soto C, Gorman J, et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature. 2014; 514: 455–461. doi: 10.1038/nature13808 25296255
13. Mörner A, Douagi I, Forsell MN, Sundling C, Dosenovic P, O'Dell S, et al. Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein. J Virol. 2009; 83: 540–51. doi: 10.1128/JVI.01102-08 19004960
14. Kovacs JM, Nkolola JP, Peng H, Cheung A, Perry J, Miller CA, et al. HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proc Natl Acad Sci USA. 2012; 109: 12111–6. doi: 10.1073/pnas.1204533109 22773820
15. Khattar SK, Samal S, LaBranche CC, Montefiori DC, Collins PL, Samal SK, Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector. PLoS One. 2013; 8: e78521. doi: 10.1371/journal.pone.0078521 24098600
16. Yasmeen A, Ringe R, Derking R, Cupo A, Julien JP, Burton DR, et al. Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. Retrovirology. 2014; 11: 41. doi: 10.1186/1742-4690-11-41 24884783
17. Huang J, Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature. 2014; 515: 138–142. doi: 10.1038/nature13601 25186731
18. Morgan C, Marthas M, Miller C, Duerr A, Cheng-Mayer C, Desrosiers R, et al. The use of nonhuman primate models in HIV vaccine development. PLoS Med. 2008; 5: e173. doi: 10.1371/journal.pmed.0050173 18700814
19. Clayton JA, Collins FS, Policy: NIH to balance sex in cell and animal studies. Nature. 2014; 509: 282–3. 24834516
20. Mohanram V, Demberg T, Tuero I, Vargas-Inchaustegui D, Pavlakis GN, Felber BK, et al. Improved flow-based method for HIV/SIV envelope-specific memory B-cell evaluation in rhesus macaques. J Immunol Methods. 2014; 412: 78–84. doi: 10.1016/j.jim.2014.06.012 24953216
21. Demberg T, Mohanram V, Venzon D, Robert-Guroff M, Phenotypes and distribution of mucosal memory B-cell populations in the SIV/SHIV rhesus macaque model. Clin Immunol. 2014; 153: 264–76. doi: 10.1016/j.clim.2014.04.017 24814239
22. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard J, et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med. 1999; 189: 991–8. 10075982
23. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science. 1999; 283: 857–60. 9933172
24. Patterson LJ, Malkevitch N, Venzon D, Pinczewski J, Gómez-Román VR, Wang L, et al. Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol. 2004; 78: 2212–21. 14963117
25. Vaccari M, Trindade CJ, Venzon D, Zanetti M, Franchini G, Vaccine-induced CD8+ central memory T cells in protection from simian AIDS. J Immuno. 2005; 175: 3502–7.
26. Malkevitch NV, Patterson LJ, Aldrich MK, Wu Y, Venzon D, Florese RH, et al. Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses. Virology. 2006; 353: 83–98. 16814356
27. Manrique M, Kozlowski PA, Wang SW, Wilson RL, Micewicz E, Montefiori DC, et al. Nasal DNA-MVA SIV vaccination provides more significant protection from progression to AIDS than a similar intramuscular vaccination. Mucosal Immunol. 2009; 2: 536–50. doi: 10.1038/mi.2009.103 19741603
28. Martins MA, Wilson NA, Reed JS, Ahn CD, Klimentidis YC, Allison DB, et al. T-cell correlates of vaccine efficacy after a heterologous simian immunodeficiency virus challenge. J Virol. 2010; 84: 4352–65. doi: 10.1128/JVI.02365-09 20164222
29. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature. 2011; 473: 523–7. doi: 10.1038/nature10003 21562493
30. Stephenson KE, Li H, Walker BD, Michael NL, Barouch DH, Gag-specific cellular immunity determines in vitro viral inhibition and in vivo virologic control following simian immunodeficiency virus challenges of vaccinated rhesus monkeys. J Virol. 2012; 86: 9583–9. doi: 10.1128/JVI.00996-12 22761379
31. Lakhashe SK, Wang W, Siddappa NB, Hemashettar G, Polacino P, Hu SL, et al. Vaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protection. PLoS One. 2011; 6: e22010. doi: 10.1371/journal.pone.0022010 21799765
32. Manrique M, Kozlowski PA, Cobo-Molinos A, Wang SW, Wilson RL, Martinez-Viedma M del P, et al. Resistance to infection, early and persistent suppression of simian immunodeficiency virus SIVmac251 viremia, and significant reduction of tissue viral burden after mucosal vaccination in female rhesus macaques. J Virol. 2014; 88: 212–24. doi: 10.1128/JVI.02523-13 24155376
33. Xiao P, Patterson LJ, Kuate S, Brocca-Cofano E, Thomas MA, Venzon D, et al. Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge. J Virol. 2012; 86: 4644–57. doi: 10.1128/JVI.06812-11 22345466
34. Xiao P, Zhao J, Patterson LJ, Brocca-Cofano E, Venzon D, Kozlowski PA, et al. Multiple vaccine-elicited non-neutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol. 2010; 84: 7161–7173. doi: 10.1128/JVI.00410-10 20444898
35. Bomsel M, Tudor D, Drillet AS, Alfsen A, Ganor Y, Roger MG, et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity. 2011; 34: 269–280. doi: 10.1016/j.immuni.2011.01.015 21315623
36. Bolton DL, Song K, Wilson RL, Kozlowski PA, Tomaras GD, Keele BF, et al. Comparison of systemic and mucosal vaccination: impact on intravenous and rectal SIV challenge. Mucosal Immunol. 2012; 5: 41–52. doi: 10.1038/mi.2011.45 22031182
37. Brocca-Cofano E, McKinnon K, Demberg T, Venzon D, Hidajat R, Xiao P, et al. Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia. Vaccine. 2011; 29: 3310–9. doi: 10.1016/j.vaccine.2011.02.066 21382487
38. Yates NL, Liao HX, Fong Y, deCamp A, Vandergrift NA, Williams WT, et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med. 2014; 6: 228ra39. doi: 10.1126/scitranslmed.3007730 24648342
39. Nimmerjahn F, Ravetch JV, Fcγ receptors as regulators of immune responses. Nat Rev Immunol. 2008; 8: 34–47. 18064051
40. Vargas-Inchaustegui DA, Robert-Guroff M, Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention. Curr HIV Res. 2013; 11: 407–420. 24191937
41. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA, The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol. 2007; 25: 21–50. 17029568
42. Okazaki A, Shoji-Hosaka E, Nakamura K, Wakitani M, Uchida K, Kakita S, et al. Fucose depletion from human IgG1 and oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcγRIIIa. J Mol Biol. 2004; 336: 1239–49. 15037082
43. Niwa R, Natsume A, Uehara A, Wakitani M, Iida S, Uchida K, et al. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J Immunol Meth. 2005; 306: 151–60.
44. Forthal DN, Gach JS, Landucci G, Jez J, Strasser R, Kunert R, et al. Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12. J Immunol. 2010; 185: 6876–82. doi: 10.4049/jimmunol.1002600 21041724
45. Chung AW, Crispin M, Pritchard L, Robinson H, Gorny MK, Yu X, et al. Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function. AIDS. 2014; 28: 2523–30. doi: 10.1097/QAD.0000000000000444 25160934
46. Ackerman ME, Crispin M, Yu X, Baruah K, Boesch AW, Harvey DJ, et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J Clin Invest. 2013; 123: 2183–92. doi: 10.1172/JCI65708 23563315
47. Chen G, Wang Y, Qiu L, Qin X, Liu H, Wang X, et al. Human IgG Fc-glycosylation profiling reveals associations with age, sex, female sex hormones and thyroid cancer. J Proteomics. 2012; 75: 2824–34. doi: 10.1016/j.jprot.2012.02.001 22365975
48. To KKW, Zhang AJX, Hung KFN, Xu T, Ip WCT, Wong RTY, et al. High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza. Clin Vac Immunol. 2012; 19: 1012–7.
49. Kim JH, Excler JL, Michael NL, Lessons from the RV144 Thai Phase III HIV-1 vaccine trial and the search for correlates of protection. Annu Rev Med. 2015; 66: 6.1–6.15.
50. Takada A, Kawaoka Y, Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol. 2003; 13: 387–98. 14625886
51. Forthal DN, Gabriel EE, Wang A, Landucci G, Phan TB, Association of Fcγ receptor IIIa genotype with the rate of HIV infection after gp120 vaccination. Blood. 2012; 120: 2836–42. doi: 10.1182/blood-2012-05-431361 22915639
52. Pennell LM, Galligan CL, Fish EN, Sex affects immunity. J Autoimmun. 2012; 38: 282–91.
53. Sankaran-Walters S, Macal M, Grishina I, Nagy L, Goulart L, Coolidge K, et al. Sex differences matter in the gut: effect on mucosal immune activation and inflammation. Biol Sex Differ. 2013; 4: 10–12. doi: 10.1186/2042-6410-4-10 23651648
54. Goode D, Aravantinou M, Jarl S, Truong R, Derby N, Guerra-Perez N, et al. Sex hormones selectively impact the endocervical mucosal microenvironment: implications for HIV transmission. PLoS One. 2014; 9: e97767. doi: 10.1371/journal.pone.0097767 24830732
55. Honda K, Littman DR, The microbiome in infectious disease and inflammation. Annu Rev Immunol. 2012; 30: 759–95. doi: 10.1146/annurev-immunol-020711-074937 22224764
56. Markle JG, Fish EN, SeXX matters in immunity. Trends Immunol. 2014; 35: 97–104. doi: 10.1016/j.it.2013.10.006 24239225
57. Salas JT, Chang TL, Microbiome in human immunodeficiency virus infection. Clin Lab Med. 2014; 34: 733–45. doi: 10.1016/j.cll.2014.08.005 25439273
58. Wira CR, Rodriguez-Garcia M, Shen Z, Patel M, Fahey JV, The role of sex hormones and the tissue environment in immune protection against HIV in the female reproductive tract. Am J Reprod Immunol. 2014; 72: 171–81. doi: 10.1111/aji.12235 24661500
59. Vishwanathan SA, Guenthner PC, Lin CY, Dobard C, Sharma S, Adams DR, et al. High susceptibility in repeated, low-dose vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques. J Acquir Immune Defic Syndr. 2011; 57: 261–4. doi: 10.1097/QAI.0b013e318220ebd3 21546848
60. Saba E, Grivel JC, Vanpouille C, Brichacek B, Fitzgerald W, Margolis L, et al. HIV-1 sexual transmission: early events of HIV-1 infection of human cervico-vaginal tissue in an optimized ex vivo model. Mucosal Immunol. 2010; 3: 280–90. doi: 10.1038/mi.2010.2 20147895
61. Kovats S, Estrogen receptors regulate an inflammatory pathway of dendritic cell differentiation: mechanisms and implications for immunity. Hormones and Behavior. 2012; 62: 254–62. doi: 10.1016/j.yhbeh.2012.04.011 22561458
62. Khaksari M, Keshavarzi Z, Gholamhoseinian A, Bibak B, The effect of female sexual hormones on the intestinal and serum cytokine response after traumatic brain injury: different roles for estrogen receptor subtypes. Can J Physiol Pharmacol. 2013; 91: 700–7. doi: 10.1139/cjpp-2012-0359 23984641
63. Looijer-van Langen M, Hotte N, Dieleman LA, Albert E, Mulder C, Madsen KL, Estrogen receptor-β signaling modulates epithelial barrier function. Am J Physiol Gastrointest Liver Physiol. 2011; 300: G621–6. doi: 10.1152/ajpgi.00274.2010 21252046
64. Wada-Hiraike O, Imamov O, Hirakie H, Hultenby K, Schwend T, Omoto Y, et al. Role of estrogen receptor β in colonic epithelium. Proc Natl Acad Sci USA. 2006; 103: 2959–64. 16477031
65. O’Mahony F, Thomas W, Harvey BJ, Novel female sex-dependent actions of oestrogen in the intestine. J Physiol. 2009; 587: 5039–44. doi: 10.1113/jphysiol.2009.177972 19723780
66. Diebel ME, Diebe LN, Manke CW, Liberati DM, Estrogen modulates intestinal mucus physiochemical properties and protects against oxidant injury. J Trauma Acute Care Surg. 2014; 78: 94–9.
67. Hill L, Jeganathan V, Chinnasamy P, Grimaldi C, Diamond B, Differential roles of estrogen receptors α and β in control of B-cell maturation and selection. Mol Med. 2011; 17:211–20. doi: 10.2119/molmed.2010.00172 21107497
68. Lu FX, Abel K, Ma Z, Rourke T, Lu D, Torten J, et al. The strength of B cell immunity in female rhesus macaques is controlled by CD8+ T cells under the influence of ovarian steroid hormones. Clin Exp Immunol. 2002; 128: 10–20. 11982585
69. Report on the global AIDS epidemic—2012. www.unaids.gov.
70. Srivastava IK, Kan E, Sun Y, Sharma VA, Cisto J, Burke B, et al. Comparative evaluation of trimeric envelope glycoproteins derived from subtype C and B HIV-1 R5 isolates. Virology. 2008; 372: 273–90. 18061231
71. Lee EM, Chung HK, Livesay J, Suschak J, Finke L, Hudacik L, et al. Molecular methods for evaluation of virological status of nonhuman primates challenged with simian immunodeficiency or simian-human immunodeficiency viruses. J Virol Methods. 2010; 163: 287–94. doi: 10.1016/j.jviromet.2009.10.012 19878696
72. Romano JW, Shurtliff RN, Dobratz E, Gibson A, Hickman K, Markham PD, et al. Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology. J Virol Methods. 2000; 86: 61–70. 10713377
73. Strbo N, Vaccari M, Pahwa S, Kolber MA, Doster MN, Fisher E, et al. Cutting edge: novel vaccination modality provides significant protection against mucosal infection by highly pathogenic simian immunodeficiency virus. J Immunol. 2013; 190: 2495–9. doi: 10.4049/jimmunol.1202655 23401588
74. Pegu P, Vaccari M, Gordon S, Keele BF, Doster M, Guan Y, et al. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. J Virol. 2013; 87: 1708–19. doi: 10.1128/JVI.02544-12 23175374
75. Demberg T, Brocca-Cofano E, Xiao P, Venzon D, Vargas-Inchaustegui D, Lee EM, et al. Dynamics of memory B-cell populations in blood, lymph nodes, and bone marrow during antiretroviral therapy and envelope boosting in simian immunodeficiency virus SIVmac251-infected rhesus macaques. J Virol. 2012; 86: 12591–604. doi: 10.1128/JVI.00298-12 22973034
76. Montefiori DC, Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol. 2005; 12: 11.
77. Gómez-Román VR, Florese RH, Patterson LJ, Peng B, Venzon D, Aldrich K, et al. A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J Immunol Methods. 2006; 308: 53–67. 16343526
78. Ackerman ME, Moldt B, Wyatt RT, Dugast AS, McAndrew E, Tsoukas S, et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods. 2011; 366: 8–19. doi: 10.1016/j.jim.2010.12.016 21192942
79. Patterson LJ, Daltabuit-Test M, Xiao P, Zhao J, Hu W, Wille-Reece U, et al. Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge. Virology. 2011; 411: 87–102. doi: 10.1016/j.virol.2010.12.033 21237474
80. Bertley FM, Kozlowski PA, Wang SW, Chappelle J, Patel J, Sonuyi O, et al. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. J Immunol. 2004; 172: 3745–57. 15004179